Atopic Dermatitis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

All the vital news, analysis, and commentary curated by our industry experts.

$17995

Buy Report Download FREE Resources

Published: January 29, 2026 Report Code: GDHC336PIDR-ST

Report Overview
Key Players
Table of Contents
Table
Figures

This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Atopic Dermatitis market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033.

GlobalData estimated that the atopic dermatitis market was $8.5 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $21.5 billion, increasing at a compound annual growth rate (CAGR) of 9.8%. This strong growth will be fuelled by driven by the launch of seven late-stage pipeline agents, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast period.

Scope

Overview of AD – including epidemiology, disease etiology and management.

Topline AD drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.

Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.

Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Develop business strategies by understanding the trends shaping and driving the seven-market atopic dermatitis (AD) therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the seven-market AD therapeutics market from 2023-2033.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AbbVie
Aclaris Therapeutics
Almirall
Amgen
AOBiome Therapeutics
Apollo Therapeutics
Arcutis Biotherapeutics
Dermavant Sciences
Eli Lilly
Evommune
Galderma
ImageneBio
Incyte
Kymera Therapeutics
Kyowa Kirin
Leo Pharma
Maruho
Nektar Therapeutics
Organon
Otsuka
Pfizer
Regeneron
Sanofi
UCB
Union Therapeutics

List of Contents

List of Tables

List of Figures

1 Atopic Dermatitis: Executive Summary

1.1 AD market to experience significant growth from 2023–33

1.2 New players set to enter AD market

1.3 Opportunities remain for the treatment of AD

1.4 Novel systemic therapies dominate the late-stage pipeline

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumption and methods: 12-month diagnosed prevalent cases of AD

4.4.4 Forecast assumptions and methods: 12-month diagnosed prevalent cases of AD by severity

4.5 Epidemiological Forecast for AD (2023–33)

4.5.1 12-month diagnosed prevalent cases of AD

4.5.2 Age-specific 12-month diagnosed prevalent cases of AD

4.5.3 Sex-specific 12-month diagnosed prevalent cases of AD

4.5.4 12-month diagnosed prevalent cases of AD by severity

4.6 Discussion

4.6.1 COVID-19 impact

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 KOL insights on disease management

5.2.1 Treatment approach

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 More personalized treatments through improved diagnosis

7.3 High cost of therapeutics

7.4 Lack of therapeutic options for CHE

7.5 Better long-term disease control and management

8 R&D Strategies

8.1 Overview

8.1.1 Rise of the JAK inhibitors

8.1.2 Rise of IL-inhibiting biologics

8.1.3 Personalized approach for AD

8.1.4 Promising effects of anti-OX40/OX40L therapies

8.2 Clinical trials design

8.2.1 Clinical trial design in AD

8.2.2 Clinical trial design in CHE

8.2.3 H2H in AD

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

9.2.1 Mild to moderate AD agents

9.2.2 Moderate-to-severe agents

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

10.2.1 Systemic agents

10.2.2 Topical agents

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs and payers interviewed for this report

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Managing Analyst

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Reviewers

13.6.6 Vice President of Disease Intelligence and Epidemiology

13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Table

Table 1: AD: Key metrics in the 7MM

Table 2: Risk factors and comorbidities for AD

Table 3: Treatment guidelines for AD

Table 4: AD approvals across 7MM

Table 5: Top 10 deals by value, 2019–25

Table 6: AD market – global drivers and barriers, 2023–33

Table 7: Key events impacting sales for AD in the US, 2023–33

Table 8: AD market – drivers and barriers in the US, 2023–33

Table 9: Key events impacting sales for AD in the 5EU, 2023–33

Table 10: AD market – drivers and barriers in the 5EU, 2023–33

Table 11: Key events impacting sales for AD in Japan, 2023–33

Table 12: AD market – drivers and barriers in Japan, 2023–33

Table 13: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Seven-Market sales forecast by country for AD in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in AD during the forecast period

Figure 3: Competitive assessment of the marketed and pipeline systemic drugs benchmarked against the SOC, Dupixent

Figure 5: Major drug targets in AD treatment

Figure 6: 7MM, 12-month diagnosed prevalence of AD, %, all ages, 2023

Figure 7: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the adult population

Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population

Figure 9: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the adult population by severity

Figure 10: 7MM, sources used to forecast the 12-month diagnosed prevalent cases of AD in the pediatric population by severity

Figure 11 presents the 12-month diagnosed prevalent cases of AD in the 7MM in 2023.

Figure 11: 7MM, 12-month diagnosed prevalent cases of AD, N, both sexes, all ages, 2023

Figure 12: 7MM, 12-month diagnosed prevalent cases of AD by age, N, both sexes, 2023

Figure 13 presents the 12-month diagnosed prevalent cases of AD by sex in the 7MM in 2023.

Figure 13: 7MM, 12-month diagnosed prevalent cases of AD by sex, N, all ages, 2023

Figure 14 presents the 12-month diagnosed prevalent cases of AD by severity in the 7MM in 2023.

Figure 14: 7MM, 12-month diagnosed prevalent cases of AD by severity, both sexes, N, all ages, 2023

Figure 15: Flowchart of the diagnosis and management of AD, according to AAD

Figure 16: Unmet needs and opportunities in AD

Figure 17: Overview of the development pipeline in AD

Figure 18: Key late-stage trials for the promising mild-to-moderate pipeline agents that GlobalData expects to be licensed for AD in the 7MM during the forecast period

Figure 19: Key late-stage trials for promising moderate-to-severe pipeline agents that GlobalData expects to be licensed for AD in the 7MM during the forecast period

Figure 20: Competitive assessment of marketed and pipeline systemic drugs benchmarked against the SOC, Dupixent

Figure 21: Competitive assessment of the marketed and pipeline topical drugs, benchmarked against the SOC, TCs.

Figure 22: Analysis of the company portfolio gap in AD during the forecast period, 2023–33

Figure 23: Global (7MM) sales forecast by country for AD in 2023 and 2033

Figure 24: Global (7MM) Sales Forecast by MOA for AD in 2023 and 2033

Figure 25: Sales forecast by class for AD in the US in 2023 and 2033

Figure 26: Sales forecast by class for AD in the 5EU in 2023 and 2033

Figure 27: Sales forecast by class for AD in Japan in 2023 and 2033

Atopic Dermatitis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports

Currency USD

Single User

$17,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Atopic Dermatitis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Atopic Dermatitis (Atopic Eczema) reports

Pharmaceuticals

New

Human Immunodeficiency Virus (HIV) Major Markets: Disease Management, Epidemiology, Pipeline…

Pharmaceuticals

New

Catalyst Monitor: Q2 2026 Outlook

Pharmaceuticals

New

Emerging Market Outsourcing Report, Q1 2026

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Atopic Dermatitis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

Access a live Atopic Dermatitis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Atopic Dermatitis Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports